Trial Profile
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Nicotine abuse vaccine (Primary)
- Indications Smoking withdrawal; Substance-related disorders
- Focus Registrational; Therapeutic Use
- 08 May 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 08 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jul 2011 Primary endpoint 'Clinical-response' has not been met.